Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
F 44.85 2.47% 1.08
RLAY closed up 2.47 percent on Friday, January 15, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical RLAY trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.47%
Crossed Above 20 DMA Bullish 2.47%
MACD Bullish Signal Line Cross Bullish 2.47%
Pocket Pivot Bullish Swing Setup 2.47%
Volume Surge Other 2.47%
Older End-of-Day Signals for RLAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 1 day ago
Up 3% 1 day ago
20 DMA Support 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 57.59
52 Week Low 32.56
Average Volume 496,532
200-Day Moving Average 0.00
50-Day Moving Average 46.86
20-Day Moving Average 43.42
10-Day Moving Average 40.75
Average True Range 3.78
ADX 22.15
+DI 20.73
-DI 19.06
Chandelier Exit (Long, 3 ATRs ) 39.45
Chandelier Exit (Short, 3 ATRs ) 47.69
Upper Bollinger Band 50.58
Lower Bollinger Band 36.27
Percent B (%b) 0.6
BandWidth 32.95
MACD Line -1.47
MACD Signal Line -1.81
MACD Histogram 0.3424
Fundamentals Value
Market Cap 4.04 Billion
Num Shares 90 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -45.30
Price-to-Sales 0.00
Price-to-Book 6.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.34
Resistance 3 (R3) 50.08 48.00 49.43
Resistance 2 (R2) 48.00 46.60 48.13 49.12
Resistance 1 (R1) 46.42 45.73 47.21 46.68 48.81
Pivot Point 44.34 44.34 44.73 44.47 44.34
Support 1 (S1) 42.76 42.94 43.55 43.02 40.89
Support 2 (S2) 40.68 42.07 40.81 40.58
Support 3 (S3) 39.10 40.68 40.28
Support 4 (S4) 39.36